Sign in and IndoyangAI keeps you up to date on Korea and India every day: industry news in four languages, market reports, regulatory changes explained in plain words, and an assistant that answers your questions about all of it.
Korea's bio and pharma policy focus over the past week has been speeding up domestic new-drug development, building rules for digital and AI-driven products, and aligning with global regulators. Here is where things stand.
Korea–India industry digest · Free · members-only section
Korea's health ministry convened industry and government on November 18 to review domestic new drug development, noting 45 approved home-grown drugs and a 6% global share of drug candidates. The drug safety regulator also marked the 40th Pharmacy Day and issued two medical device guidelines.
Korea–India industry digest · Free · members-only section
Over the past three weeks, Korea's Ministry of Food and Drug Safety has put AI, digital medical devices and digital convergence medicines at the centre of its agenda. Alongside, Seoul has eased medicine access, tightened online enforcement and raised its international regulatory profile.
Korea–India industry digest · Free · members-only section
Korea's Ministry of Food and Drug Safety held two days of industry consultations on digital convergence medicines and digital medical devices, alongside events on AI-based quality control and innovative devices. It also reported 571 online illegal drug sales and brokering cases ahead of the college entrance exam.
Korea–India industry digest · Free · members-only section
Korea's Ministry of Food and Drug Safety spent early November raising its international profile and tightening oversight at home, while the government pushes to grow 200 frontier pharma-bio companies.
Korea–India industry digest · Free · members-only section
Korea's health and drug authorities spent early November widening access to medicines and raising the country's regulatory standing abroad. Industry policy is aimed at 200 pharma-bio frontier companies and a sovereign AI-bio strategy.
Korea–India industry digest · Free · members-only section
Korea's pharma and device regulators spent the past three weeks expanding medicine access, adding safety measures and building international ties. Seoul is also backing industrial plans for AI-driven bio and 200 frontier firms.
Korea–India industry digest · Free · members-only section
Korea's health and drug authorities spent the past three weeks widening access to medicines, tightening safety oversight and raising their international profile. Industry policy is building alongside, with plans for 200 pharma-bio frontier firms and a sovereign AI-bio strategy.
Korea–India industry digest · Free · members-only section
Korea's health ministry has proposed rules to bring household medicines to military units, small regional airports and island ferries without nearby pharmacies. Drug regulators also announced steps on GLP-1 drug safety, PIC/S assessment work and fee reform.